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Abstract
Introduction: Several anhepatic pig models were developed in the past. Most models suffer from short anhepatic
survival times due to insufficient postoperative intensive care unit (ICU) management. The aim of this study was to
analyze anhepatic survival time under standardized intensive care therapy in a pig model.
Methods: Eight pigs underwent total hepatectomy after Y-graft interposition between the infrahepatic vena cava
and the portal vein to the suprahepatic vena cava. An intracranial probe was inserted for intracranial pressure (ICP)
monitoring. Animals received pressure-controlled ventilation under deep narcosis. Vital parameters were
continuously recorded. Urinary output, blood gas analysis, haemoglobin, hematocrit, serum electrolytes, lactate, and
glucose were monitored hourly, and creatinine, prothrombin time, international normalised ratio, and serum
albumin were monitored every 8 hours. Sodium chloride solution 0.9%, hydroxyethyl starch 6%, fresh frozen
plasma, and erythrocyte units were used for volume substitution, and norepinephrine was used to prevent severe
hypotension. Serum electrolytes and acid-base balance were corrected as required. Antibiotic prophylaxis with
ceftriaxon was given daily, as well as furosemide, to maintain diuresis.
Results: Postoperative survival was 100% after 24 hours, with a maximum survival of 73 (mean, 58 ± 4) hours.
Haemodynamic parameters such as heart rate, mean arterial pressure, and pulse oximetry remained stable during
surgical procedures and following anhepatic status due to ICU therapy until escalating at time of death.
Deteriorating pulmonary function could be stabilized by increasing oxygen concentration, positive end-expiratory
pressure, and maximal airway pressure. Furosemide was used to maintain diuresis until renal failure occurred. ICP
started at 15-17 mmHg and increased continuously up to levels of 41-43 mmHg at time of death. All animals died
as a result of multiple-organ failure.
Conclusions: Using standardized intensive care management after total hepatectomy, we were able to prolong
anhepatic survival over 58 hours without the use of liver support systems. The survival benefit of liver support
systems in previous animal studies should be reevaluated against our model.
Introduction
Several models of acute hepatic failure have been inves-
tigated in animal studies [1-3] to analyze bioartificial
[4-6] or artificial [7] liver support technologies as treat-
ment options to bridge until transplantation or to sup-
port liver regeneration. In these models, hepatic failure
was achieved by intoxication with galactosamine or
acetaminophen [8-10], hepatic ischemia by portocaval
shunting following transient clamping of the hepatic
artery [11,12], and extended resection or even total
hepatectomy [13-21]. Unfortunately, all aforementioned
models involve various limitations, thus affecting mor-
bidity in the assessment of a given intervention.
Advantages of the anhepatic model [22] are its repro-
ducibility and its potential to assess the efficiency of
artificial or bioartificial liver support systems in vivo in
the absence of toxic products leaking out of or produced
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operation is technically complex but well reproducible.
Our newly developed technique [23] allows total
hepatectomy in haemodynamically stable animals due to
lateral clamping of large blood vessels.
A review of the management of experimental anhepa-
tic coma in various pig models showed several treatment
strategies. They vary completely from almost no post-
operative treatment at all [24] to mechanical ventilation
and supportive therapy with colloid fluid resuscitation
and catecholamines [19]. Considering this fact, it is
astonishing that none of the previous anhepatic models
established any standardized intensive care therapy or
used supportive therapy, which has been established in
humans for the past decade [25]. Furthermore, survival
times between studies showed major variations from 10
to 45 hr. These survival rates may be judged as a control
group because it is ethically not justifiable to kill
animals to verify insufficient therapy.
Postoperative critical care medicine management by
itself has an important impact on anhepatic survival.
Moreover, well-intended established procedures such as
fluid resuscitation may impair coagulation homeostasis,
thus possibly complicating outcome. Therefore, it is
important to use a reproducible animal model as a tool
for screening a given intervention with high validity to
improve hepatic failure outcome. The aim of our study
was the establishment of a highly reproducible anhepatic
pig model with standardized postoperative intensive care
management, which offers long-term survival to evaluate
new treatment strategies such as artificial or bioartificial
liver support systems.
Materials and methods
Experimental design
After approval by the institutional review board for ani-
mal experiments, eight female German Landrace pigs
weighing between 32 and 46 (mean, 37.4) kg underwent
total hepatectomy. All experiments were performed
according to the international principles governing
research on animals and under the supervision of a
veterinarian, who set the guidelines for minimizing the
pigs’ suffering.
Anaesthesia
Intramuscular premedication was administered using
atropine 0.1% (0.05 mg/kg), ketamine (7 mg/kg), azaper-
one (10 mg/kg), and diazepam (1 mg/kg). Adequate
temperature (approximately 38.5°C) was maintained
with a warming blanket. Two 18-gauge venous catheters
(Vasofix; Braun Melsungen, Germany) were inserted
into auricular veins for volume substitution preventing
hypovolemia, and a 20-gauge central venous catheter
(Cavafix; Braun Melsungen, Germany) was placed
through one 18-gauge catheter for intravenous anaesthe-
sia during the surgical procedure. A stomach tube
(Argyle; Tyco Healthcare, Tullamore, Ireland) was
placed for intestinal drainage. After oral intubation with
a cuffed endotracheal tube (Lo-Contour Magill; Mal-
linckrodt Medical, Athlone, Ireland), the pigs were ven-
tilated with pressure-controlled ventilation to deliver a
tidal volume of 6-10 ml/kg with a respiratory rate of 8-
12 breaths per minute (Galileo Gold; Hamilton Medical,
Rhaezuens, Switzerland). Arterial blood gas analysis
(ABL 625; Radiometer, Copenhagen, Denmark) was per-
formed hourly, and ventilation was adjusted accordingly.
Continuous infusion of ketamine (15 mg/kg/h), fentanyl
(0.02 mg/kg/h), and midazolam (0.9 mg/kg/h) was admi-
nistered to maintain anaesthesia during the study. Char-
acter of respiration, heart rate, eye movement, and pain
stimulus was used to confirm depth of anaesthesia; if
any of these parameters indicated a lessening of anaes-
thesia, infusion rates of anaesthetic agents were
increased.
Surgical procedure
In brief, animals were kept under standard laboratory
conditions and fasted for 24 hr before surgery. They
received an antibiotic prophylaxis of 2 g ceftriaxon
(Rocephin; Hoffmann-La Roche, Basel, Switzerland). The
superior vena cava through the jugular veins and the
internal carotid artery were instrumented to measure
arterial (Leadercath; Vygon, Écouen, France) and central
venous pressure (Multi-Lumen Central Venous Cathe-
ter; Arrow International, Reading, PA, USA). Following
parietofrontal cranial trepanation, a probe was inserted
into the frontal brain parenchyma to measure intracra-
nial pressure and brain temperature (Camino MPM-1
monitor; Integra Neurosciences, Plainsboro, NJ, USA).
The abdominal cavity was entered through a midline
abdominal incision, and a urinary catheter (Gentle-Flo;
Tyco Healthcare, Tullamore, Ireland) was placed. The
portal vein and the infrahepatic vena cava were mobi-
lized and prepared for anastomosis with the Y-graft vas-
cular prosthesis (Uni-Graft K DV; ITV, Denkendorf,
Germany). The diaphragm was opened on the left side
for the suprahepatic anastomosis. Performing an end-to-
side anastomosis between the Y-graft and first the infra-
hepatic vena cava, then the portal vein, and finally the
suprahepatic vena cava, lateral clamping was applied
consecutively to only one third of the vessels. End-to-
side anastomosis allowed partial clamping, thus prevent-
ing serious congestion of the intestine and a decline in
systemic blood pressure. The supra- and infrahepatic
vena cava and the portal vein were clamped totally and
ligated, and blood flow was released through the bypass.
Afterward, the hepatoduodenal ligament was ligated,
and the liver was removed en bloc,i n c l u d i n gt h e
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abdominal wall was closed with a running suture. Dur-
ing surgery, sodium chloride solution 0.9% and hydro-
xyethyl starch 6% (Voluven HES 130/0.4; Fresenius, Bad
Homburg, Germany) were infused, adjusted for mean
arterial and central venous pressure. Blood loss caused
by the blood volume remaining in the liver ranged from
300 to 700 ml and was substituted with donor erythro-
cytes and fresh frozen plasma units. Furosemide (1 mg/
kg) was given to obtain high urine output during the
surgical procedure. Two hours after surgery, the pigs
were transferred to the animal critical care unit.
Preparation of donor fresh-frozen plasma units and
erythrocyte units
All donor pigs were tested for A-O blood group anti-
gens to avoid A-O incompatible transfusion reactions.
Blood was collected in standard blood bag systems (500
m l ,C o m p o f l e x ;F r e s e n i u sH e m o C a r e ,B a dH o m b u r g ,
Germany) and centrifuged at 2500 g for 20 min (Her-
aeus Cryofuge 5500i; Thermo Electron Corporation,
Langenselbold, Germany). Plasma fraction was pressed
into separate bags and shock-frozen at -80°C. Erythro-
cytes were conserved with 100 ml SAG-M and stored at
4°C for a maximum of 7 days. Immediately before trans-
fusion, a cross-match test was done to test for compat-
ibility. Haemolysis was excluded by centrifugating a 1-
m lb l o o ds a m p l ea t5 , 0 0 0g for 10 minutes (Heraeus
Labofuge 300; Thermo Electron Corporation, Langensel-
bold, Germany).
Goals of haemostasis and haemodynamics [see Additional
file 1]
Animals remained under general anaesthesia, receiving
pressure-controlled ventilation until conclusion of the
study protocol (15-30 breaths/minute, tidal volume 6-12
ml/kg, and FiO2 0.3-1.0, depending on oxygenation).
Monitoring throughout the experiment included ECG,
arterial, central venous and intracranial pressure, oxygen
saturation, and core body temperature. Urinary output,
haemoglobin, hematocrit and lactate, serum electrolytes,
acid-base balance, blood gases, and blood glucose levels
were monitored hourly and immediately corrected as
required. PT, INR, and serum albumin were measured
before, after, and every 8 hr after hepatectomy until
death. All blood samples were obtained from the arterial
catheter. Norepinephrine, in combination with fresh-fro-
zen plasma, hydroxyethyl starch 6% (Voluven HES 130/
0.4; Fresenius, Bad Homburg, Germany), and sodium
chloride solution 0.9% were used to ensure haemody-
namic stability. Blood glucose levels were maintained at
>100 mg/dl with glucose 20% solution. Packed erythro-
cyte units were given if haemoglobin levels were <6 g/
dl. If renal failure occurred, pigs received furosemide
(maximum 1,000 mg/d) to maintain diuresis as long as
possible. Antibiotic prophylaxis (2 g ceftriaxon; Hoff-
mann-La Roche, Basel, Switzerland) was given daily.
Death was defined as decline of mean arterial pressure
below 30 mmHg under maximal ICU therapy.
Postmortem examinations were performed to verify
the patency of the vascular graft, absence of bleeding
complications, and amount and type of ascites. Histolo-
gical studies of the kidney and brain were performed in
exemplary cases.
Statistical analysis
Mean values of the selected variables determined before,
during, and after hepatectomy were compared by t-test
(JMP 4.0; SAS Institute, Cary, NC, USA). A P value
<0.01 was considered significant. Results are reported as
means ± standard deviations. Figures are given as means
± standard error of the mean.
Results
Postoperative survival was 100% after 24 hr. No signs of
portal hypertension or intestinal congestion were
noticed during the entire observation period.
All animals died of progressive liver failure between 44
and 73 hr after hepatectomy; mean survival time was 58
± 4 hours. Approximately 24 hours after hepatectomy,
all animals began to develop multiple-organ failure due
to liver insufficiency with continuous deterioration of
renal and pulmonary function. Urinary output remained
stable with furosemide, but finally decreased continu-
o u s l yw h e nr e n a lf a i l u r eo c c u r r e da tt h ee n do ft h e
experiment and was paralleled by an increase in serum
creatinine levels (Figure 1).
Haemodynamic variables such as heart rate (HR),
mean arterial pressure (MAP), central venous pressure
( C V P ) ,a n do x y g e ns a t u r a t i o n( S p O 2)r e m a i n e ds t a b l e
for the majority of the experiment in all animals
(Figure 2) but then deteriorated a few hours before
death [see Additional file 2].
To maintain sufficient oxygenation and ventilation,
tidal volume was adjusted to 8-12 ml/kg by increasing
positive end-expiratory pressure (PEEP), maximal airway
pressure (Pmax)a n dF i O 2 (Figure 3). Rising arterial CO2
tension suggested increasing dead space, particularly as
minute ventilation was increased to address hypercapnia
or indicated increased shunt volume (Figure 4, [see
Additional file 3]).
Intracranial pressure was recorded in exemplary ani-
mals. It started at elevated levels of 15-17 mmHg due to
the unphysiological supine position and then increased
to 41-43 mmHg upon death.
Lactate levels of 8.1 ± 2 mM in the early postoperative
period decreased after haemodynamic stabilization and
increased to 11.2 ± 4 mM upon death (Figure 5).
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Page 4 of 8PT and plasma proteins remained stable thanks to con-
tinuous replacement with fresh frozen plasma.
Upon autopsy, massive ascites (2,000 to 3,000 ml)
were found in all animals; no signs of intestinal conges-
tion were noticed, and all interposition grafts were
found to be regularly patent without evidence of bleed-
ing. No pericardial effusion or macroscopic signs of
myocardial damage inducing decreased contractility
could be observed. Kidneys were swollen and showed
hemorrhagic infarctions; histological examinations
confirmed tubular necrosis. Histological examination of
the brain revealed massive oedema.
Discussion
Several different animal models have been developed to
evaluate the efficacy and safety of artificial or bioartifi-
cial liver support systems during acute liver failure.
Acute hepatic failure is achieved through intoxication,
ischemia, extensive liver resection, or hepatectomy. Ter-
blanche et al. [26] first postulated high reproducibility
of liver failure models, death due to liver failure, and
defined the development time for the detection of thera-
peutic effects. Large animal models of acute hepatic fail-
ure using hepatotoxins such as galactosamine have a
poor clinical relevance. Acetaminophen intoxication
models suffer from difficulties in adjusting the adequate
dosage of toxins, with undesirable effects of toxins pro-
voking early death due to cardiocirculatory failure
within 6.5 hr [27], which possibly could be avoided by
adequate intensive care therapy. Methemoglobin forma-
tion and resulting respiratory failure were identified as
major problems in intravenously administered acetami-
nophen intoxication models. In contrast to our model,
standardized intensive care management, including fluid
resuscitation, catecholamines, and mechanical ventila-
tion to minimize toxic effects of acetaminophen, has
never been established. It is likely that survival in acute
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Page 5 of 8liver failure could be increased by using adequate inten-
sive care therapy.
While only a model of total hepatectomy with a loss
of the entire functional liver tissue may be able to iso-
late the effectiveness of a liver support system, anhepatic
models have been criticized because of the lack of toxic
compounds coming from the necrotic liver [26] and the
absence of chance for spontaneous regeneration. Anhe-
patic situations in patients caused by major surgical
traumas or hyperacute rejection after liver transplanta-
tion are very rare in clinical practice but are discussed
controversially as a rescue option.
Our newly developed technique [23] allows total hepa-
tectomy in haemodynamically stable animals due to lat-
eral clamping of large blood vessels. Standardized
critical care management has made a significant impact
on outcome. Considering this fact, it is astonishing that
none of the previous models of acute hepatic failure
gave pigs any standardized critical care therapy; such
therapy has been established in humans for the past
decade [25].
A review of the management of experimental anhepa-
tic coma in various pig models showed treatment strate-
gies to vary completely from no treatment at all [24] to
mechanical ventilation and supportive therapy with col-
loid fluid resuscitation and catecholamines [19]. After
surgery, our animals remained under general anaesthesia
and received maximal critical care support, including
mechanical ventilation, catecholamines, diuretics, and
other medication if required.
Since encephalopathy could not be judged clinically by
character of respiration, in contrast to previous studies
in which pigs were allowed to wake up and breathe
spontaneously after hepatectomy [14,21,24,28], in our
study intracranial pressure was monitored to obtain at
least a surrogate for cerebral function.
Survival time without mechanical ventilation in other
models ranged from about 10 [28] to 17 hr [14] in pre-
vious studies in contrast to about 34 [29], 46 [19], and
our result of 58 ± 4 hr with continuous mechanical ven-
tilation. These results clearly show that continuous
mechanical ventilation is needed in anhepatic models
because increasing intracranial pressure otherwise
results in hypoxia and subsequent death.
End-stage liver failure is characterized by a loss of vas-
cular autoregulation, resulting in vasodilatation and
severe hypotension. In most porcine models, hypoten-
sion was treated only with crystalloid or colloid fluid
resuscitation, without catecholamines to compensate for
developing circulation failure. Using phenylephrine or
norepinephrine in combination with colloid fluid resus-
citation, fresh frozen plasma and erythrocyte units pro-
vided considerably longer survival, at least in our study
as compared with all previously reported studies. Our
results clearly show that standardized intensive care
medicine in our model of acute hepatic failure pro-
longed anhepatic survival and improved outcome
significantly.
While these differences in intensive care management
in animal models may be simply epiphenomena of the
device and/or strategy being studied, they must be
acknowledged as such as well. For example, if subopti-
mal critical care support produces low survival times
that may be prolonged with a given liver support sys-
tem, a false-positive result favouring a given liver sup-
port system may result. When extrapolating such
observations, it is possible that laboratory results are
transferred to a clinical intensive care medicine setting
where a liver support system is unable to provide any
benefit. Accordingly, when these bench-to-bedside dif-
ferences are not appropriately accounted for, additional
technology may no longer be superior to standard ther-
apy. Since our survival times are about two to four
times longer than those for currently established models,
we suggest that our model might serve as a tough tool
for evaluating liver support systems. Therefore, pro-
longed survival gained by different bioreactors has to be
reevaluated and compared with a standard intensive
care control group. A combination of artificial or bioar-
tificial liver support systems with standard intensive care
therapy should improve considerably the survival times
of our animal model. The point of principle if a liver
support system is superior to intensive care in the stabi-
lisation of the haemodynamic situation, respiration, or
appearance of brain oedema in the further course of
anhepathy can easily be answered.
Conclusions
Careful intensive care support enabled survival for about
60 hr in an anhepatic porcine model and may thus be a
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support technologies.
Key messages
￿ Standardized intensive care treatment improves
survival in a large animal model for acute liver
failure.
￿ This treatment alone is superior to most developed
treatment strategies using liver support devices.
￿ Using standardized intensive care treatment pro-
longs the therapeutic window for the application of
new liver support devices or other strategies.
Additional material
Additional file 1: ICU Management. Algorithms for volume
resuscitation, vasopressor support and management of mechanical
ventilation.
Additional file 2: Course of haemodynamic parameters and
electrolytes. Haemodynamic parameters, electrolytes and body
temperature with respect to time and resuscitation.
Additional file 3: Course of ventilation parameters. Ventilation
parameters and body temperature with respect to time and resuscitation.
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